$2.06
0.96%
Nasdaq, Sep 18, 04:00 pm EDT. Closed.
ISIN
KYG831161065
Symbol
MENS

Jyong Biotech Stock price

$2.06
+0.04 1.98% 1M
+0.27 15.08% 6M
-1.89 47.85% YTD
-49.69 96.02% 1Y
-5.44 72.53% 3Y
-5.44 72.53% 5Y
-5.44 72.53% 10Y
-5.44 72.53% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-0.02 0.96%
ISIN
KYG831161065
Symbol
MENS
Industry

Is Jyong Biotech a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
$152.9m
Enterprise Value
$170.2m
Net debt
$17.3m
Cash
$1.2m
Shares outstanding
74.2m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
-119.9%
Return on Equity
18.8%
ROCE
24.4%
ROIC
-21.3%
Debt/Equity
-0.7
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-3.3m
EBIT
$-3.4m
Net Income
$-5.9m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
-
Short interest
0.5%
Employees
27
Rev per Employee
$0.0

Financial data from Jyong Biotech

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.24 2.24
-
-
- Research and Development Expense 1.10 1.10
-
-
-3.34 -3.34
-
-
- Depreciation and Amortization 0.08 0.08
-
-
EBIT (Operating Income) EBIT -3.42 -3.42
-
-
Net Profit -5.92 -5.92
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Jyong Biotech directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jyong Biotech Stock News

Neutral
GlobeNewsWire
18 days ago
New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.
Neutral
GlobeNewsWire
about 2 months ago
New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today reaffirmed its strategic focus on pursuing global licensing partnerships to address the growing medical needs in the urology secto...
Neutral
GlobeNewsWire
3 months ago
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25...
More Jyong Biotech News

Company Profile

Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei City, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.

Head office Cayman Islands
CEO Ms. Kuo
Employees 27
Website jyongbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today